Sucrosomial iron

Sucrosomial iron is a new oral iron preparation containing ferric pyrophosphate covered by phospholipids plus sucrose ester of fatty acid matrix. This allows the molecule to be absorbed in the gastrointestinal tract by trans-cellular, para-cellular and M-cells independently of hepcidin and due to gastro-resistant properties, it does not cause the side effects such as gastric irritation which is commonly associated to oral iron.

The higher bioavailability of sucrosomial iron means that a lower oral iron dose can be used to be achieving a similar improvement in trasferrin levels.

References

↑ Gascon, Pere (2012-10-31), "Bone Marrow Toxicity: Red Blood Cells", Side Effects of Medical Cancer Therapy, Springer London, pp. 333–364, doi:10.1007/978-0-85729-787-7_8, ISBN 978-0-85729-786-0, retrieved 2020-04-08
↑ Gómez-Ramírez, Susana; Brilli, Elisa; Tarantino, Germano; Muñoz, Manuel (2018-10-04). "Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation". Pharmaceuticals. 11 (4): 97. doi:10.3390/ph11040097. ISSN 1424-8247. PMC 6316120. PMID 30287781.
↑ Michalak, Sylwia Sulimiera (2020-12-01). "Iron deficiency anemia – new possibilities of iron supplementation in various clinical conditions". Acta Haematologica Polonica. 51 (4): 212–219. doi:10.2478/ahp-2020-0037.
↑ Valerii, Maria Chiara; Dussias, Nikolas Kostantine; Perri, Anna; Spigarelli, Renato; Bernacchi, Alberto; Rizzello, Fernando; Magri, Gianluigi; Gionchetti, Paolo; Spisni, Enzo (October 2026). "Reduced-dose alternate-day oral iron supplementation in women with iron deficiency: a randomized controlled trial". European Journal of Nutrition. 65 (8). doi:10.1007/s00394-026-04139-9.

[1] Gascon, Pere (2012-10-31), "Bone Marrow Toxicity: Red Blood Cells", Side Effects of Medical Cancer Therapy, Springer London, pp. 333–364, doi:10.1007/978-0-85729-787-7_8, ISBN 978-0-85729-786-0, retrieved 2020-04-08

[2] Gómez-Ramírez, Susana; Brilli, Elisa; Tarantino, Germano; Muñoz, Manuel (2018-10-04). "Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation". Pharmaceuticals. 11 (4): 97. doi:10.3390/ph11040097. ISSN 1424-8247. PMC 6316120. PMID 30287781.

[3] Michalak, Sylwia Sulimiera (2020-12-01). "Iron deficiency anemia – new possibilities of iron supplementation in various clinical conditions". Acta Haematologica Polonica. 51 (4): 212–219. doi:10.2478/ahp-2020-0037.

[4] Valerii, Maria Chiara; Dussias, Nikolas Kostantine; Perri, Anna; Spigarelli, Renato; Bernacchi, Alberto; Rizzello, Fernando; Magri, Gianluigi; Gionchetti, Paolo; Spisni, Enzo (October 2026). "Reduced-dose alternate-day oral iron supplementation in women with iron deficiency: a randomized controlled trial". European Journal of Nutrition. 65 (8). doi:10.1007/s00394-026-04139-9.